Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
Efficient Preference Poisoning Attack on Offline RLHF
arXiv:2605.02495v2 Announce Type: replace-cross Abstract: Offline Reinforcement Learning from Human Feedback (RLHF) pipelines such as Direct Preference Optimization (DPO) train on a pre-collected preference dataset, which makes them vulnerable to preference poisoning attack. We study label flip attacks against log-linear DPO. We first illustrate that flipping one preference label induces a parameter-independent shift in the DPO gradient. Using this key property, we can then convert the targeted
-
cs.AI, q-bio.NC updates on arXiv.org
-
MuDD: A Multimodal Deception Detection Dataset and GSR-Guided Progressive Distillation for Non-Contact Deception Detection
arXiv:2603.26064v2 Announce Type: replace-cross Abstract: Non-contact automatic deception detection remains challenging because visual and auditory deception cues often lack stable cross-subject patterns. In contrast, galvanic skin response (GSR) provides more reliable physiological cues and has been widely used in contact-based deception detection. In this work, we leverage stable deception-related knowledge in GSR to guide representation learning in non-contact modalities through cross-modal
MuDD: A Multimodal Deception Detection Dataset and GSR-Guided Progressive Distillation for Non-Contact Deception Detection
-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
Spatial Omics in Gastrointestinal Oncology: Recent Advances, Therapeutic Insights, and Clinical Translation
J Cancer. 2026 Jan 30;17(3):515-523. doi: 10.7150/jca.127381. eCollection 2026.ABSTRACTGastrointestinal (GI) cancers remain a leading cause of cancer-related morbidity and mortality worldwide, largely due to their molecular heterogeneity, complex tumor microenvironment (TME), and variable treatment responses. In recent years, the emergence of spatially resolved omics technologies-encompassing spatial transcriptomics, proteomics, metabolomics, and epigenomics-has revolutionized the ability to int
Spatial Omics in Gastrointestinal Oncology: Recent Advances, Therapeutic Insights, and Clinical Translation
J Cancer. 2026 Jan 30;17(3):515-523. doi: 10.7150/jca.127381. eCollection 2026.
ABSTRACT
Gastrointestinal (GI) cancers remain a leading cause of cancer-related morbidity and mortality worldwide, largely due to their molecular heterogeneity, complex tumor microenvironment (TME), and variable treatment responses. In recent years, the emergence of spatially resolved omics technologies-encompassing spatial transcriptomics, proteomics, metabolomics, and epigenomics-has revolutionized the ability to interrogate tumor architecture with unprecedented resolution. These methods enable precise mapping of cellular and molecular interactions within intact tissue contexts, thereby uncovering spatially defined niches that influence tumor progression, immune evasion, and therapeutic resistance. In GI malignancies such as colorectal, gastric, and esophageal cancers, spatial omics have provided critical insights into cancer-stromal-immune crosstalk, identified predictive biomarkers for immunotherapy and targeted agents, and guided the development of novel therapeutic strategies. This review synthesizes the latest advances in spatial omics applied to GI oncology over the past five years, with an emphasis on their integration into early diagnosis, treatment stratification, and real-time monitoring of therapeutic efficacy. We also discuss current challenges, including standardization, data integration, and clinical validation, as well as future directions for incorporating spatial profiling into routine oncology practice. By bridging the gap between bench discoveries and bedside applications, spatial omics hold transformative potential for achieving truly personalized treatment in gastrointestinal cancers.
PMID:41869445 | PMC:PMC13003551 | DOI:10.7150/jca.127381
-
Nature - Issue - nature.com science feeds
-
Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma
Nature, Published online: 11 March 2026; doi:10.1038/s41586-026-10244-wA clinical trial testing whether monitoring ctDNA clearance during treatment for nasopharyngeal cancer could be used to inform decisions about an individual’s subsequent therapeutic programme shows promising results.
Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma
Nature, Published online: 11 March 2026; doi:10.1038/s41586-026-10244-w
A clinical trial testing whether monitoring ctDNA clearance during treatment for nasopharyngeal cancer could be used to inform decisions about an individual’s subsequent therapeutic programme shows promising results.